Sharenet Sites 
Sharenet Sites
Form 8-K/A Current Report
ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")
FORM 8-K/A CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, ASPI stockholders are advised
that a Form 8-K/A (Amendment No.1) has been filed with the U.S. Securities and Exchange Commission.
On January 7, 2026, ASP Isotopes Inc. (the "Company" or "ASP Isotopes") filed with the Securities and
Exchange Commission a Current Report on Form 8-K (the "Closing Form 8-K") reporting the completion,
on January 6, 2026, of the previously announced acquisition (the "Transaction") contemplated by the firm
intention letter agreement, dated May 20, 2025, by and between ASP Isotopes and Renergen Limited, a
public company incorporated under the laws of the Republic of South Africa focused on production of
liquefied helium (LHe) and liquefied natural gas (LNG) ("Renergen"), pursuant to which, subject to the terms
and conditions thereof, ASP Isotopes acquired all of the issued ordinary shares of Renergen in exchange
for shares of ASP Isotopes common stock through the implementation of a scheme of arrangement in
accordance with Sections 114 and 115 of the South African Companies Act, No. 71 of 2008. As a result of
the Transaction, Renergen became a direct, wholly owned subsidiary of the Company.
At the time of the filing of the Closing Form 8-K, the Company stated that it intended to file the required
financial statements and pro forma financial information associated with the Transaction within 71 days
from the date that such Closing Form 8-K was required to be filed. By this Amendment No. 1 to the Closing
Form 8-K ("Form 8-K/A"), the Company is amending and restating Item 9.01 thereof to include the required
financial statements and pro forma financial information, which are filed as exhibits hereto and are
incorporated herein by reference.
The unaudited pro forma combined condensed financial statements included in this Form 8-K/A have been
presented for informational purposes only, as required by Form 8-K, do not purport to represent the actual
results of operations that the Company and Renergen would have achieved had the companies been
combined during the periods presented in the pro forma financial statements, and are not intended to project
the future results of operations that the combined company may achieve after the Transaction.
Except as described above, all other information in the Closing Form 8-K remains unchanged.
A copy of the Form 8-K/A can also be found at: Inline Viewer: ASP Isotopes Inc. 8-K/A 2026-01-06
The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.
25 March 2026
Sponsor
Valeo Capital Proprietary Limited
Date: 25-03-2026 09:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
